Abstract：
UGN-101 has been approved for the chemoablation of low-grade upper tract urothelial cancer (UTUC) involving the renal pelvis and calyces. Herein is the first reported cohort of patients with ureteral tumors treated with UGN-101.
We performed a retrospective review of patients treated with UGN-101 for UTUC at 15 high-volume academic and community centers focusing on outcomes of patients treated for ureteral disease. Patients received UGN-101 with either adjuvant or chemo-ablative intent. Response rates are reported for patients receiving chemo-ablative intent. Adverse outcomes were characterized with a focus on the rate of ureteral stenosis.
In a cohort of 132 patients and 136 renal units, 47 cases had tumor involvement of the ureter, with 12 cases of ureteral tumor only (8.8%) and 35 cases of ureteral plus renal pelvic tumors (25.7%). Of the 23 patients with ureteral involvement who received UGN-101 induction with chemo-ablative intent, the complete response was 47.8%, which did not differ significantly from outcomes in patients without ureteral involvement. Fourteen patients (37.8%) with ureteral tumors had significant ureteral stenosis at first post-treatment evaluation, however, when excluding those with pre-existing hydronephrosis or ureteral stenosis, only 5.4% of patients developed new clinically significant stenosis.
UGN-101 appears to be safe and may have similar efficacy in treating low-grade urothelial carcinoma of the ureter as compared to renal pelvic tumors.
We performed a retrospective review of patients treated with UGN-101 for UTUC at 15 high-volume academic and community centers focusing on outcomes of patients treated for ureteral disease. Patients received UGN-101 with either adjuvant or chemo-ablative intent. Response rates are reported for patients receiving chemo-ablative intent. Adverse outcomes were characterized with a focus on the rate of ureteral stenosis.
In a cohort of 132 patients and 136 renal units, 47 cases had tumor involvement of the ureter, with 12 cases of ureteral tumor only (8.8%) and 35 cases of ureteral plus renal pelvic tumors (25.7%). Of the 23 patients with ureteral involvement who received UGN-101 induction with chemo-ablative intent, the complete response was 47.8%, which did not differ significantly from outcomes in patients without ureteral involvement. Fourteen patients (37.8%) with ureteral tumors had significant ureteral stenosis at first post-treatment evaluation, however, when excluding those with pre-existing hydronephrosis or ureteral stenosis, only 5.4% of patients developed new clinically significant stenosis.
UGN-101 appears to be safe and may have similar efficacy in treating low-grade urothelial carcinoma of the ureter as compared to renal pelvic tumors.
摘要：
目的：UGN-101已被批准用于低级别上尿路上皮癌（UTUC）的化学消融，涉及肾盂和肾盏。本文是第一个报道的用UGN-101治疗的输尿管肿瘤患者队列。
方法：我们在15个大型学术和社区中心对接受UGN-101治疗UTUC的患者进行了回顾性研究，重点关注输尿管疾病患者的治疗结果。患者接受具有辅助或化学消融意图的UGN-101。报告了接受化学消融意图的患者的反应率。不良结局的特点是关注输尿管狭窄的发生率。
结果：在132名患者和136个肾脏单位的队列中，肿瘤累及输尿管47例,仅输尿管肿瘤12例(8.8%)，输尿管加肾盂肿瘤35例(25.7%)。在23例输尿管受累患者中，接受了UGN-101诱导并伴有化学消融意图，完全缓解率为47.8%,这与没有输尿管受累的患者的结局没有显着差异。14例（37.8%）输尿管肿瘤患者在首次治疗后评估时出现明显的输尿管狭窄，然而,当排除先前存在肾积水或输尿管狭窄的患者时，只有5.4%的患者出现新的临床显著狭窄.
结论：与肾盂肿瘤相比，UGN-101似乎是安全的，在治疗输尿管低度尿路上皮癌中可能具有相似的疗效。
方法：我们在15个大型学术和社区中心对接受UGN-101治疗UTUC的患者进行了回顾性研究，重点关注输尿管疾病患者的治疗结果。患者接受具有辅助或化学消融意图的UGN-101。报告了接受化学消融意图的患者的反应率。不良结局的特点是关注输尿管狭窄的发生率。
结果：在132名患者和136个肾脏单位的队列中，肿瘤累及输尿管47例,仅输尿管肿瘤12例(8.8%)，输尿管加肾盂肿瘤35例(25.7%)。在23例输尿管受累患者中，接受了UGN-101诱导并伴有化学消融意图，完全缓解率为47.8%,这与没有输尿管受累的患者的结局没有显着差异。14例（37.8%）输尿管肿瘤患者在首次治疗后评估时出现明显的输尿管狭窄，然而,当排除先前存在肾积水或输尿管狭窄的患者时，只有5.4%的患者出现新的临床显著狭窄.
结论：与肾盂肿瘤相比，UGN-101似乎是安全的，在治疗输尿管低度尿路上皮癌中可能具有相似的疗效。
